Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkTreatment with Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients with Cancer

Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial

The rates of grades 2, 3, 4, and 5 toxic effects were 14.2%, 4.2%, 0%, and 0.3%, respectively, in this population-based phase 2 nonrandomized clinical trial of 381 patients with oligometastatic or oligoprogressive disease that was designed to capture toxic effects prospectively as the primary end point.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form